Jyotirmoy Roy

Jyotirmoy Roy

Auto-generated profile, based on publicly available information

Jyotirmoy Roy

Department of Biomedical Engineering University of Michigan Ann Arbor Michigan USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2021 in Journal of microbiology, epidemiology and immunobiology
Verified
Journal Article
Open access
PDF file
SASh. Aggarwal
Sh. Aggarwal
SPShashwati parihari
Shashwati parihari
ABA. Banerjee
A. Banerjee
JRJ. Roy
J. Roy
NBN. Banerjee
N. Banerjee
Sanjeeva SrivastavaSanjeeva Srivastava
Sanjeeva Srivastava
Introduction. COVID-19 has become a global impediment by bringing everything to a halt starting from January 2020. India underwent the lockdown starting from 22nd March 2020 with the sudden spike in the number of COVID-19 patients in major cities and states. This study focused on how metabolites play a crucial role in SARSCoV-2 prognosis.Materials and methods. Metabolome profiling of 106 plasma samples and 24 swab samples from symptomatic patients in the Indian population of the Mumbai region was done. COVID-19 positive samples were further segregated under the non-severe COVID-19 and severe COVID-19 patient cohort for both plasma and swab.Results. After analyzing the raw files, total 7,949 and 12,871 metabolites in plasma and swab were found. 11 and 35 significantly altered metabolites were found in COVID-19 positive compared to COVID-19 negative plasma and swab samples, respectively. Also, 9 and 23 significantly altered metabolites were found in severe COVID-19 positive to non-severe COVID-19 positive plasma and swab samples, respectively. The majorly affected pathways in COVID-19 patients were found to be the amino acid metabolism pathway, sphingosine metabolism pathway, and bile salt metabolism pathway.Conclusion. This study facilitates identification of potential metabolite-based biomarker candidates for rapid diagnosis and prognosis for clinical applications.

8 October 2026 in Advanced Science
Verified
Journal Article
Open access
PDF file
JRJyotirmoy Roy
Jyotirmoy Roy
ANAbdalmonam Jadou Nejma
Abdalmonam Jadou Nejma
MTMohammad Tarique
Mohammad Tarique
ATAmod Talekar
Amod Talekar
SWShengli Wu
Shengli Wu
LSLonnie D Shea
Lonnie D Shea
Islet transplantation can restore glycemic control in type 1 diabetes, yet heterogeneity of immune responses and transplant outcomes necessitates improved graft monitoring. Since transplanted islets are diffusely engrafted within the liver and inaccessible to biopsy, clinical monitoring relies on blood glucose and C‐peptide, which change only after substantial graft injury. Here, we developed a synthetic immunological niche (IN) that captures graft‐associated immune responses through serial subcutaneous biopsy. We evaluated the IN across murine syngeneic, allogeneic, and autoimmune islet transplant models, including CD40/CD154 blockade with anti‐CD40L. The IN identified immune populations and transcriptomic signatures reflective of the graft and distinguished syngeneic from rejecting allografts. In anti‐CD40L‐treated allografts, the IN revealed innate immune programs characterized by macrophage‐ and dendritic cell‐associated signatures linked to acceptance versus rejection, whereas untreated allografts showed stronger adaptive immune signatures. Longitudinal IN profiling detected inflammatory activation in accepted allografts, indicating persistent subclinical risk. Finally, in autoimmune allografts treated with anti‐CD40L plus rapamycin, IN identified a 13‐gene signature that separated early from late rejection and distinguished autoimmune‐ from alloimmune‐associated rejection programs. These findings establish the IN as a platform for identification of early biomarkers of islet graft rejection before overt dysfunction, addressing an unmet need in islet transplant monitoring.

20 November 2026 in Bioengineering & Translational Medicine
Verified
Journal Article
Open access
KKKathryn Kang
Kathryn Kang
GDGrace K. Darlak
Grace K. Darlak
JTJian Toy
Jian Toy
HKHanna Kim
Hanna Kim
JMJames Messina
James Messina
LSLonnie D Shea
Lonnie D Shea
Current methods for detecting metastasis rely on patient self‐reporting of symptoms and late‐stage imaging, thereby limiting early detection and opportunities for intervention at low disease burden. Herein, we developed an injectable biomaterial scaffold that functions as a synthetic metastatic niche, enabling the assessment of immune responses in distant tissues reflective of disease progression. The scaffolds were fabricated using a top‐down approach to create an open‐top cubic structure and were delivered into the subcutaneous space with fibrin. These scaffolds recruited immune cells that were subsequently isolated for downstream analysis. Gene expression profiling of the isolated cells was used to generate a score that reflects disease progression. Finally, we demonstrated the feasibility of fine‐needle aspiration as a minimally invasive biopsy approach to collect cells from the scaffolds, which recapitulated scores indicative of disease progression. These injectable scaffolds, functioning as a synthetic metastatic niche, enable longitudinal assessment of metastatic disease.